1 Article tittle: "Clinical, Radiological and Therapeutic Characteristics of Patients with COVID-

- 2 19 in Saudi Arabia"
- 3 Authors' names:
- 4 Mohammed Shabrawishi, M.D,^{1,2} Manal M Al-Gethamy, M.D,³ Abdallah Y Naser, PhD,⁴ Maher A Ghazawi,
- 5 M.D,⁵ Ghaidaa F Alsharif, M.D,² Elaf F Obaid, M.D,² Haitham A Melebari, M.D,⁶ Dhaffer M Alamri,³ Ahmad
- 6 S Brinji, M.D,⁵ Fawaz H Al Jehani, M.D,⁷ Wail Almaimani, M.D,⁷ Rakan A Ekram, M.D,⁸ Kasim H Alkhatib,
- 7 M.D,⁹ Hassan Alwafi, M.D¹⁰

8 Authors affiliations:

- ¹Department of Respiratory Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.
- 10 ²Department of Internal Medicine, Al Noor Specialist Hospital, Mecca, Saudi Arabia.
- ³Department of Infection Prevention and Control Programme, Al Noor Specialist Hospital, Mecca, Saudi
 Arabia.
- ⁴Faculty of Pharmacy, Isra University, Amman, Jordan.
- ⁵Department of Radiology, Al Noor Specialist Hospital, Mecca, Saudi Arabia.
- ⁶Department of Internal Medicine, King Faisal General Hospital, Mecca, Saudi Arabia.
- 16 ⁷Al Noor Specialist Hospital, Mecca, Saudi Arabia.
- ⁸School of Public Health and Health Informatics, Umm Al Qura University, Mecca, Saudi Arabia.
- ⁹Intensive Care Department, Al Noor Specialist Hospital, Mecca, Saudi Arabia.
- ¹⁰Department of Clinical Pharmacology and Toxicology, Faculty of Medicine, Umm Al Qura University,
 Mecca, Saudi Arabia.

21

22 Corresponding author

- 23 Dr.Hassan Alwafi
- 24 Department of Clinical Pharmacology and Toxicology
- 25 Umm Alqura University, Faculty of Medicine
- 26 Mecca, Saudi Arabia
- 27 Post Code 24381
- 28 T+966555544319
- 29 Email: hhwafi@uqu.edu.sa
- 30 Number of words in abstract: 249 words
- 31 Number of words in main body text: 2,633 words
- 32 Number of tables in main body text: 4 table
- 33 Number of figures in main body text: 3 figures
- 34 Number of references in main body text: 34

35 Abstract (249)

36 BACKGROUND

Coronavirus disease 2019 (COVID-19) is a rapidly spreading global pandemic. The clinical characteristics of COVID-19 has been reported; however, there are limited researches that investigated the clinical characteristics of COVID-19 in the Middle East. The aim of this study is to investigate the clinical, radiological and therapeutic characteristics of patients diagnosed with COVID19 in Saudi Arabia.

42 METHODS

This study is a retrospective single-centre case series study. We extracted data for patients who were admitted to the Al-Noor Specialist hospital with a PCR confirmed SARS-COV-2 between 12th and 31st of March 2020. Descriptive statistics were used to describe patients' characteristics. Continuous data were reported as mean \pm SD. Chi-squared test/Fisher test were used as appropriate to compare proportions for categorical variables.

48 **RESULTS**

A total of 150 patients were hospitalised for COVID-19 during the study period. The mean age was 46.1 years (SD: 15.3 years). Around 61.0% (n= 90) were males and six patients (3.9%) reported working in the healthcare sector. The most common comorbidities were hypertension (28.8%, n= 42) and diabetes mellitus (26.0%, n= 38). The majority of the patients, 64.4% (n = 96) had a recent contact history with a COVID patient. Regarding the severity of the hospitalised patients, 105 patients (70.0%) were mild, 29 (19.3%) were moderate, and 16 patients (10.7%) were severe or required ICU care. From the 105 mild patients, around 31.3% (n= 47) were asymptomatic.

56 CONCLUSION

57 This case series provides clinical, radiological and therapeutic characteristics of hospitalised patients58 with confirmed COVID-19 in Saudi Arabia.

59 KEYWORDS

60 Clinical Characteristics, COVID-19, Retrospective case series, Radiological SARS-Cov2

61

62 **1. INTRODUCTION**

In early December 2019, a cluster of acute pneumonia of unknown aetiology has been identified in Wuhan, China (1). The pathogen has been identified as a new RNA virus from the betacoronavirus family, and has been named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2). The respiratory illness caused by the 2019 novel coronavirus disease (COVID-19) is highly infectious, and therefore, the World Health Organization (WHO) has characterized the diseases a pandemic infection (3). As of April 25, 2020, more than 2,700,000 confirmed cases were reported worldwide, and it has spread from Wuhan to more than 200 countries across the world (4).

The Kingdom of Saudi Arabia (KSA) is the largest country in the Arabian Peninsula and it is located in the South West part of Asia (5). In a historical decision, KSA has suspended Umrah and all religious visits to the country in an attempt to prevent and delay the spread of COVID-19 in KSA. However, in March 2, 2020, Saudi Arabia has confirmed its first case of COVID-19 which was imported from Iran (4). Several other local clusters were identified later with the majority of the cases being linked to recent travel history.

76 In recent studies, the clinical features and severity of COVID-19 has been described to be similar of 77 other respiratory viruses such as severe acute respiratory syndrome (SARS) and Middle East 78 respiratory syndrome (MERS) (6, 7). Symptoms can range from mild flu-like symptoms to acute 79 respiratory distress syndrome (ARDS) (8). However, the characteristics and the course of the disease 80 in Middle Eastern populations remains unclear. Exploring the clinical characteristics of patients 81 diagnosed with COVID-19 in Saudi Arabia is important knowing that there are many visitors who 82 travel to Saudi Arabia for religious purposes. Beside this, there is a high air traffic for other purposes 83 in this country which was estimated to be around 39 million people in 2018. In 2019, around 7.5 84 million Muslim entered the holy city of Mecca for Umrah purposes (9). This highlights how crucial is 85 to have a deeper exploration on the characteristics of patients diagnosed with this widespread 86 infection in this region. To address the above knowledge gaps and giving the ongoing spread of 87 COVID-19 in the Middle East, this study aims to describe the clinical, radiological, and therapeutic 88 characteristics of COVID-19 in a selected cohort of patients in Mecca, Saudi Arabia.

89 **2. METHODS**

90 **2.1. Study Design and participants**

This was a retrospective single-centre case series study of 150 patients diagnosed with COVID-19. We extracted data for patients who were admitted to Al-Noor Specialist hospital with a polymerase chain reaction (PCR) confirmed SARS-COV-2 between 12th and 31st of March 2020. Al-Noor Specialist hospital in Mecca, Saudi Arabia is a 500-bedder specialist and teaching hospital in the centre of the holy city of Mecca. It delivers tertiary care throughout the Mecca region of Saudi Arabia

and its part of the Ministry of Health services (10, 11). All patients enrolled in this study were
diagnosed with COVID-19 through real time (RT)-PCR obtained through nasopharyngeal swabs. All
data including outcomes, mortality and length of stay were monitored up to 8th April 2020.

99 2.2. Data Collection

100 Data were extracted from both paper and electronic records using a unique medical record number 101 (MRN) for each patient. All data were reviewed and checked by a medical team including; two 102 medical residents and a consultant Pulmonologist. Extracted data included patients' demographics, 103 comorbidities, history of recent travel and history of contact with a confirmed COVID19 patient in the 104 past two weeks. In addition, clinical signs, symptoms, radiological findings and pharmacological 105 treatment received were collected. The radiological examinations were interpreted by a certified 106 consultant radiologist who was blinded from the clinical presentation of the patients. The severity 107 assessment of the chest x-ray (CXR) were estimated subjectively. All data were collected at the time 108 of the admission.

109 **2.3. Study variables**

110 Data regarding the clinical progression and severity of the disease were reported as the worst 111 classification reached at any point during hospitalisation. We further classified the severity of the 112 disease based on the following criteria; 1) mild disease was defined as patients with upper respiratory 113 tract symptoms (as rhinorrhoea, sore throat, headache, myalgia, body pain, low grad fever and or dry 114 cough) with absent of clinical or radiological finding of pneumonia; 2) moderate disease defined as 115 symptomatic patients with radiological sign of pneumonia; 3) severe disease defined as confirmed 116 COVID-19 pneumonia with any of the following respiratory rate \geq 30/min, blood oxygen saturation 117 \leq 93% at rest, PaO2/FiO2 ratio <300, lung infiltration >50% of the lung field, and 4) critically sever 118 disease defined as any of the following: respiratory failure required invasive mechanical ventilation, 119 shock or organ failure require admission to the intensive care unit.

120 **2.4. Ethics**

121 This study was approved by the institutional ethics board at the Ministry of Health in Saudi Arabia 122 (No. H-02-K-076-0420-286). Patients were informed that their clinical data will be used for clinical or 123 research purposes with keeping all their personal information confidential.

124 **2.5. Statistical Analysis**

125 Descriptive statistics were used to describe patients' demographic characteristics, radiological 126 findings, medications use, and comorbidities. Continuous data were reported as mean \pm SD, and 127 categorical data were reported as percentages (frequencies). Independent sample t test was used to

128 compare the mean value for continuous variables. Chi-squared test/Fisher test were used as 129 appropriate to compare proportions for categorical variables. Logistic regression analysis was used to 130 identify predictors of clinical characteristics. A confidence interval of 95% (p < 0.05) was applied to 131 represent the statistical significance of the results and the level of significance was assigned as 5%. 132 SPSS (Statistical Package for the Social Sciences) version 25.0 software (SPSS Inc) was used to 133 perform all statistical analysis.

134 **3. RESULTS**

135 **3.1. Patients clinical characteristics**

136 **Table 1** presents patients' characteristics at presentation to the hospital. A total of 150 patients were 137 hospitalised for COVID-19. The mean age was 46.1 years (SD: 15.3 years), and ranged between 11 138 and 87. Around 61.0% (n= 90) were males. Six patients (3.9%) reported working in the healthcare 139 sector. The most common comorbidities were hypertension (28.8%, n=42) and diabetes mellitus 140 (DM) (26.0%, n=38). The majority of the patients (56.0%; n=84) were local resident. Around half of 141 the patients (54.1%, n=80) reported that they had a contact history with a traveller. In addition, the 142 majority of the patients, 64.4% (n = 96) had a contact history with a COVID-19 patient. Regarding the 143 severity of the hospitalised patients, 105 patients (70.0%) were mild, 29 (19.3%) were moderate, and 144 16 patients (10.7%) were severe or required ICU care. Of the 105 mild patients, around 31.3% (n=47) 145 were asymptomatic. Patients with comorbidities were more likely to have a severe outcome compared 146 to other patients (p<0.05). Patients who reported a contact history with a COVID-19 patient were 147 more likely to have mild to moderate severity of the disease (p<0.05). Mild cases were more prevalent 148 among females, while moderate to severe and or critical were prevalent among males (Figure 1). For 149 symptomatic patients, the most common symptoms at presentation were fever (49.3%, n=72), dry cough (48.6%, n= 71), and shortness of breath (19.9%, n= 29) (Table 2). Furthermore, during 150 151 admission, fever and cough (28%) were the most common symptoms followed by nausea and 152 vomiting (12%). Most of the asymptomatic patients were females (OR: 0.45 [95% CI 0.22 - 0.92]; p= 153 0.027). In addition, patients who reported travel history or a contact with a traveller recently were 154 three times (OR: 3.13 [95%CI 1.52 – 6.45]; p= 0.002) and four times (OR: 4.03 [95%CI 1.84 – 8.81]; 155 p=0.000) more likely to be asymptomatic, respectively. Besides, patients who have reported a contact 156 with COVID-19 patients were four times at higher risk of being symptomatic (OR: 4.50 [95%CI 1.84 157 -10.99]; p= 0.001).

158 **3.2. Radiological findings**

Around half of the patients (49.7%, n= 72) had normal radiological exam at presentation. The severity
of the cases was correlated with an increase in the prevalence of GGO at presentation (P=0.002). The
predominant pattern of abnormality observed was ground-glass opacification (29.0%, n= 42),

peripheral (57.5%, n= 42), and (bilateral (35.3%, n= 35), which was mainly involving the lower lobes
(Figure 2). Most of the patients had stable radiological exams on follow up. Around 64.6% (n= 62)
showed progression, half of them belongs to more severe group (Table 3).

165 **3.3. Recovery**

166 Patients stayed at the hospital for a mean duration of 9.2 days (SD: 3.9). Duration of stay in hospital 167 ranged from two days to 23 days. At the end of the follow-up period a total of 94 patients (63.5%) 168 recovered and 31.8% (n= 47) improved clinically but RT-PCR results were still positive. On the other 169 hand, three patients (2.0%) did not fully recover and four patients (2.7%) deceased. There was no 170 statistically significant difference based on the age regarding the recovery or whether the patient was 171 symptomatic or asymptomatic upon presentation to hospital (p>0.05). The majority of the patients 172 with mild cases improved or recovered, however, there was no statistically significant difference 173 between cases from different severity and recovery rate (p>0.05) (Figure 3).

3.4. Therapeutic management

Beside supportive care, there were three main types of therapies that were prescribed to the patients
for the management of COVID-19, this includes: a) antiviral therapy, b) antibiotics, and c)
antimalarial medications (Table 4).

178 **4. DISCUSSION**

179 To the best of our knowledge, this is the first and largest study to examine the clinical characteristics 180 of COVID-19 in the Middle East region. We investigated clinical, radiological, and therapeutic 181 characteristics of COVID-19 in a 150 hospitalised patients in Saudi Arabia. We found that around 182 89.0% of the cases were either mild or moderated and only 11.0% were either severe or critical. Our 183 finding showed that the clinical severity of COVID-19 were of a milder presentation compared to 184 results from China (12), Italy (13) and the United States (14, 15). These finding could be attributed to 185 several factors including age and other demographics differences. The mean age in our study was 46.1 186 years (SD: 15.3) which was younger than the age reported in other studies. Several studies have 187 reported poorer outcome among older population and patients with COVID-19 and comorbidities (16-188 18). However, it is difficult to draw a causal inference and we urge for further studies to investigate 189 this association. In addition, it is important to highlight that the majority of the Saudi Arabian 190 population are younger than 44 years (19).

Male patients with COVID-19 were more prevalent in our study compared to females, this was also similar to previous reports which highlight more males to be infected with COVID-19 (2, 14). These numbers could be because of men sex-based immunological differences or it could also be because of behavioural patterns such as smoking (20). In addition, comorbidities are more prevalent in men

which could also be a reason for this difference (21), However, more researches must focus on genderdifferences and clinical outcomes with COVID-19.

197 Our study highlighted that around 28.8% and 26.0% of the study population had hypertension (HTN) 198 and DM, these results were similar to previous reports that investigated the clinical characteristics of 199 COVID-19 (1). Patients with DM and hypertension have an increased risk of complication of 200 COVID-19 including acute respiratory distress syndrome (ARDS) (22), however, the mechanism of 201 this remains un-investigated and it is unclear whether patients with uncontrolled blood pressure have a 202 poorer outcomes of COVID-19 compared to patients with controlled blood pressure. In addition, 203 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are two 204 commonly prescribed medications for the management of HTN, and since SARS-CoV-2, binds to 205 ACE2 in the lung, some theoretical theories have been raised about the benefits of these medications 206 in the treatment of COVID-19 (23).

207 SARS-COV2 has been described to be similar to seasonal influenza, SARS-COV and MERS, this 208 includes the fact that it is transmitted through respiratory droplets (24, 25). In addition, SARS-COV2 209 has similar symptoms to SARS-COV and MERS such as; fever, cough, and shortness of breath. This 210 was reported in our study and it was also in line with previous studies (6, 13), however, SARS-COV2 211 has a higher case fatality rate in comparison to seasonal flu (0.1%) while it is also milder in 212 comparison to other respiratory viruses such as SARS-COV (9.5%) and MERS (34.3%) (26). Besides 213 this, COVID-19 is a highly infectious pathogenic (27, 28), with some reports suggested that half of 214 the United Kingdom (UK) population has been infected without showing any symptoms or with 215 having a mild course of the disease (29). Our study demonstrated that around 31.3% of the study 216 sample were asymptomatic and had a mild disease. Mostly, these patients were identified through 217 contact tracing and were isolated in the earlier course of the disease, whether this approach have any 218 impact on the clinical course psychologically, this might need to be addressed in future studies. In 219 addition, the majority of these patients had a contact with a confirmed COVID-19 patients which may 220 raise concerns regarding the mechanism and the underlying inflammatory response in these patients. 221 More researches are encouraged to investigate the characteristics of asymptomatic patients and if 222 early detection and supportive treatment have a role in the clinical progression of the disease.

In our study, and unlike previous reports, nearly half of the patients presented with normal CXR, most of them were asymptomatic or had a mild disease. Furthermore, normal CXR at presentation may have a prognostic rule as only few numbers of those patients progressed into more severe cases. On the other hand, presence of ground glass opacity is linked with more aggressive course. The patterns found in abnormal exams were similar to the previously published reports and findings where peripheral, bilateral ground glass opacification (30).

Our study highlighted that around 26.7% of the patients received antimalarial treatment and around 9.0% received antiviral treatment, these medications have been suggested to have some beneficial effect to reduce the viral load and eliminate the disease, however, there are also uncertainties

232 regarding their safety (31, 32). In addition, there has been debate about their efficacy in the treatment 233 of COVID-19 with several trials are now in pipeline for the testing of these medications (33). To date, 234 there is no treatment for COVID-19, and the main approach in the management of the disease is to 235 provide supportive treatment and to control the symptoms including mechanical ventilator for critical 236 cases (34). This study has some limitations. First, the number of patients included in the study were 237 small. Second, the study population only included patients from a single-centre hospital in Saudi 238

Arabia.

239 5. CONCLUSION

240 This case series provides clinical, radiological, and therapeutic characteristics of hospitalised patients 241 with confirmed COVID-19 in Saudi Arabia. Our study demonstrates similar characteristics of 242 COVID-19 to previously reported studies worldwide.

243 **Conflict of interest**

244 The authors have stated explicitly that there are no conflicts of interest in connection with this article.

245 **Authors contribution**

246 Shabrawishi, Naser, Ghazawi and Alwafi had full access to all the data in the study and take

247 responsibility for the integrity of the data and the accuracy of the data analysis. Shabrawishi and

248 Alwafi had the original idea for this study. Shabrawishi, Naser and Alwafi contributed to the design of

249 the study. Obaid and Alsharif contributed to the data collection. Naser and Alwafi contributed in the

250 statistical analysis. Shabrawishi, Naser, Ekram and Alwafi wrote the first draft. All the authors

251 contributed to interpretation and edited the draft report.

252 Data availability statement

253 The data that support the findings of this study are available from the corresponding author upon reasonable

254 request.

255 **References:**

256 1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized 257 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 258 2020;323(11):1061-9.

259 2. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus 260 Disease 2019 in China. 2020.

261 3. WHO. Coronavirus disease 2019 (COVID-19)Situation Report –96 2020 [Available from: 262 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-263 covid-19.pdf?sfvrsn=a33836bb 2.

264 2020 4. Who. Coronavirus disease (COVID-19) outbreak [Available from: 265 https://www.who.int/emergencies/diseases/novel-coronavirus-2019.

266 5. MOFA. About Saudi Arabia 2020 [Available from: https://www.mofa.gov.sa/sites/mofaen/aboutKingDom/Pages/KingdomGeography46466.aspx. 267 268 6. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical 269 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive 270 study. Lancet (London, England). 2020;395(10223):507-13. 271 7. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 2020. 272 Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and Clinical 8. 273 Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA. 274 2020;323(11):1092-3. 275 9. Ebrahim SH, Memish ZA. COVID-19: preparing for superspreader potential among Umrah 276 pilgrims to Saudi Arabia. The Lancet. 2020;395(10227). 277 Zaglool DA, Khodari YA, Gazzaz ZJ, Dhafar KO, Shaker HA, Farooq MU. Prevalence of 10. 278 Intestinal Parasites among Patients of Al-Noor Specialist Hospital, Makkah, Saudi Arabia. Oman Med 279 J. 2011;26(3):182-5. 280 11. Health Al Noor Specialist Hospital 2020 [Available Mo. from: 281 http://nsh.med.sa/Pages/Home.aspx. 282 12. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 722314 Cases From the Chinese 283 284 Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. 285 Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA. 13. 286 2020;323(14):1335-. 287 14. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of 288 Covid-19 in New York City. 2020. 289 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. 15. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With 290 291 COVID-19 in the New York City Area. JAMA. 2020. 292 16. Mahase E. Covid-19: death rate is 0.66% and increases with age, study estimates. 293 2020;369:m1327. 294 Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity 17. 295 of coronavirus disease 2019: a model-based analysis. The Lancet Infectious diseases. 2020. 296 Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids 18. 297 in understanding the spread and fatality rates of COVID-19. 2020:202004911. 298 19. Statistics GAf. Statistical Yearbook of 2016 2016 [Available from: 299 https://www.stats.gov.sa/en/5305. 300 20. Wenham C, Smith J, Morgan R. COVID-19: the gendered impacts of the outbreak. Lancet 301 (London, England). 2020;395(10227):846-8. 302 gendered dimensions of COVID-19. 21. The L. The Lancet (London, England). 303 2020;395(10231):1168. 304 22. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at 305 increased risk for COVID-19 infection? The Lancet Respiratory medicine. 2020;8(4):e21. 306 Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. American 23. 307 Journal of Hypertension. 2020. 308 Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS 24. 309 and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface 310 contamination. The Journal of hospital infection. 2016;92(3):235-50. 311 WHO. Modes of transmission of virus causing COVID-19:implications for IPC precaution 25. 312 recommendations 2020 [Available from: https://www.who.int/publications-detail/modes-of-313 transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations. 314 26. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-

Z7. Zhang S, Diao M, Yu W, Pei L, Lin Z, Chen D. Estimation of the reproductive number of novel
coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A datadriven analysis. International journal of infectious diseases : IJID : official publication of the
International Society for Infectious Diseases. 2020;93:201-4.

28. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine. 2020;27(2).

322 29. Sayburn A. Covid-19: experts question analysis suggesting half UK population has been
 323 infected. 2020;368:m1216.

30. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with
COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases.
2020;20(4):425-34.

327 31. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. 2020;369:m1432.

328 32. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the 329 efficacy and safety of chloroquine for the treatment of COVID-19. Journal of critical care. 2020.

330 33. Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. The Lancet Respiratory medicine. 2020.

332 34. NICE. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in 333 the community 2020 [Available from: https://www.nice.org.uk/guidance/ng165.

334 TABLES LEGENDS

- Table 1: Patients demographic characteristics at presentation.
- 336 Table 2: Patient signs and symptoms at presentation and during admission.
- 337 Table 3: Radiological findings.
- 338 Table 4: Initial treatment characteristics.

339 FIGURES LEGENDS

- 340 Figure 1: Clinical severity stratified by gender.
- 341 Figure 2: CXR's of two different patients showing the most common abnormalities: bilateral,
- 342 peripheral ground glass opacities and consolidation
- 343 Figure 3: Recovery rates stratified by case severity

344 TABLES

345 Table 2: Patients demographic characteristics at presentation.

Demographics	All patients (n=150)	Mild cases (n=105)	Moderate cases (n=29)	Severe/Intensive care unit cases (n= 16)	P-value
Age (years; mean (SD))	46.1 years	45.4 years	46.7 years	49.8 years	0.550
	(15.3)	(±16.0)	(±12.1)	(±15.7)	
Gender					
Female No. (%)	60 (40.0)	47 (44.8)	10 (34.5)	3 (18.8)	0.112
Healthcare worker					
Yes No. (%)	6 (4.0)	6 (5.8)	0	0	0.110
Place of residency No. (%)					
Kingdom of Saudi	84 (56.0)	57 (54.3)	15 (51.7)	12 (75.0)	0.084
Arabia					
Other countries	66 (44.0)	48 (45.7)	14 (48.3)	4 (25.0)	0.239
Comorbidities No. (%)					

Hypertension	42 (28.8)	29 (27.6)	10 (35.7)	3 (23.1)	0.627
Diabetes mellitus	38 (26.0)	20 (19.0)	11 (39.3)	7 (53.8)	0.005**
Coronary artery disease	11 (7.5)	5 (4.8)	3 (10.7)	3 (23.1)	0.094
Renal disease	10 (6.8)	5 (4.8)	1 (3.6)	4 (30.8)	0.018*
Thyroid gland problem	9	4 (8.2)	2 (11.1)	3 (37.5)	0.123
(hypothyroidism)					
Asthma	4 (2.7)	3 (2.9)	0	1 (7.7)	0.306
Cancer	2 (1.4)	0	0	2 (15.4)	0.007**
CVA	1 (0.7)	1 (1.0)	0	0	0.718
COPD	1 (0.7)	0	0	1 (7.7)	0.086
CLD	1 (0.7)	0	0	1 (7.7)	0.086
Tracing history No. (%)					
Recent travel history	65 (43.9)	47 (45.6)	14 (48.3)	4 (25.0)	0.263
(Yes) No. (%)					
Contact with traveller	80 (54.1)	57 (55.3)	18 (62.1)	5 (31.3)	0.124
(Yes) No. (%)					
Contact with COVID-19	96 (64.4)	71 (68.3)	20 (69.0)	5 (31.3)	0.013*
patient (Yes) No. (%)					
Outcome (n= 148) No. (%)					
Deceased	4 (2.7)	2 (1.9)	0	2 (12.5)	0.086
Improved	47 (31.8)	37 (35.2)	6 (22.2)	4 (25.0)	0.358
Not recovered	3 (2.0)	2 (1.9)	1 (3.7)	0	0.615
Recovered	94 (63.5)	64 (61.0)	20 (74.1)	10 (62.5)	0.434

346 Abbreviations; COVID-19: coronavirus disease-2019; CVA: cerebrovascular accident; COPD: chronic

347 obstructive pulmonary disease; CLD: chronic liver disease; SD: Standard deviation; No: Number (frequency)

348 Table 2: Patient signs and symptoms at presentation and during admission.

	Sym		
Variable	At presentation	During admission No.	P-vale
	No. (%)	(%)	
Fever	72 (49.3)	28 (19.2)	0.029*
Cough	71 (48.6)	28 (19.2)	0.024*
Shortness of breath	29 (19.9)	7 (4.8)	0.000***
Sore throat	24 (16.4)	2 (1.4)	0.269
Runny nose	9 (6.2)	0 (0.0)	>0.99
Sputum	5 (3.4)	1 (0.7)	0.034*
Headache	4 (2.7)	0 (0.0)	>0.99
Myalgia	4 (2.7)	1 (0.7)	0.813
Diarrhea	2 (1.4)	5 (3.4)	0.068
Nausea/vomiting	1 (0.4)	12 (8.2)	0.678
Haemoptysis	1 (0.4)	1 (0.7)	0.887
Fatigue	1 (0.4)	1 (0.7)	0.907

349 * p<0.05; **p<0.01; ***p<0.000

350 Table 3: Radiological findings.

Radiological findings (CXR) upon admission					
	All patients (n=150)	Mild cases (n=105)	Moderate cases (n=29)	Severe/Intensive care unit cases (n= 16)	P-value
Predominant finding					
Normal	72 (49.7)	62 (60.2)	7 (25.9)	3 (20.0)	0.000***
Ground glass opacity	42 (29.0)	21 (20.4)	13 (48.1)	8 (53.3)	0.002*
Consolidation	26 (17.9)	16 (15.5)	6 (22.2)	4 (26.7)	0.488
Linear atelectasis	3 (2.1)	3 (2.9)	0	0	0.354
Diffusion reticular opacities	1 (0.7)	1 (1.0)	0	0	0.795
Reticulation	1 (0.7)	0	1	0	0.183

Distribution within the lobe					
Central	10 (13.7)	6 (14.6)	2 (10.0)	2 (16.7)	0.833
Diffuse	21 (28.8)	14 (34.1)	4 (20.0)	3 (25.0)	0.494
Peripheral	42 (57.5)	21 (51.2)	14 (70.0)	7 (58.3)	0.378
Distribution within the lung	3				
Lower	24 (32.9)	12 (29.3)	6 (30.0)	6 (50.0)	0.385
Lower middle	22 (30.1)	10 (24.4)	9 (45.0)	3 (25.0)	0.236
Lower and middle and	10 (13.7)	8 (19.5)	2 (10.0)	0	0.089
upper					
Diffuse	10 (13.7)	6 (14.6)	2 (10.0)	2 (16.7)	0.833
Peripheral	2 (2.7)	2 (4.9)	0	0	0.309
Middle	2 (2.7)	2 (4.9)	0	0	0.309
Upper	1 (1.4)	1 (2.4)	0	0	0.559
Upper and middle	1 (1.4)	0	0	1 (8.3)	0.159
No zonal predominance	1 (1.4)	0	1 (5.0)	0	0.269
Laterality					
Bilateral	53 (35.3)	27 (25.7)	16 (55.2)	10 (62.5)	0.000***
Unilateral right	12 (16.4)	10 (24.4)	2 (10.0)	0	0.035*
Unilateral left	8 (11.0)	4 (9.8)	2 (10.0)	2 (16.7)	0.805
Progression					
Stable	62 (64.6)	49 (74.2)	11 (57.9)	2 (18.2)	0.001**
Worsen	34 (35.4)	17 (25.8)	8 (42.1)	9 (81.8)	

351 CXR: chest x-ray

352 Table 4: Initial treatment characteristics.

Treatment therapy	Frequency (%)		
Antiviral therapy			
Combination of antiretroviral (lopinavir and	14 (9.3)		
ritonavir) and ribavirin			
Antimalarial therapy			
Hydroxychloroquine	25 (16.7)		
Chloroquine	15 (10.0)		
Antibiotics therapy	58 (38.7)		

353

354 FIGURES



355 356

357 Figure 1: Clinical severity stratified by gender.

358



Figure 2: CXR's of two different patients showing the most common abnormalities: bilateral,peripheral ground glass opacities and consolidation

362

359



363 364

365 Figure 3: Recovery rates stratified by case severity